ELISA Kit for Plasminogen Activator, Urokinase Receptor (uPAR)

CD87; PLAUR; PLAU-R; U-PAR; URKR; Monocyte Activation Antigen Mo3

Specificity

This assay has high sensitivity and excellent specificity for detection of Plasminogen Activator, Urokinase Receptor (uPAR).
No significant cross-reactivity or interference between Plasminogen Activator, Urokinase Receptor (uPAR) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Plasminogen Activator, Urokinase Receptor (uPAR) and the recovery rates were calculated by comparing the measured value to the expected amount of Plasminogen Activator, Urokinase Receptor (uPAR) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-101 87
EDTA plasma(n=5) 98-105 101
heparin plasma(n=5) 96-104 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Plasminogen Activator, Urokinase Receptor (uPAR) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Plasminogen Activator, Urokinase Receptor (uPAR) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Plasminogen Activator, Urokinase Receptor (uPAR) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 86-103% 95-102% 78-91% 84-92%
EDTA plasma(n=5) 85-94% 82-90% 94-102% 90-97%
heparin plasma(n=5) 99-105% 84-93% 99-105% 82-94%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
International Journal of Cancer Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice Wiley: source
Biomark Insights Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with Autism PubMed: PMC3623607
Biomarker insights Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD) PubMed: PMC3762604
Am J Emerg Med Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis PubMed: 26615223
Archives of Clinical Infectious Diseases Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis Archcid: 26346
The American Journal of Emergency Medicine Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic Cavia (Guinea pig )idance of sepsis science:S0735675715009559
Journal of Clinical and Experimental Hepatology Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) … 10.1016:j.jceh.2018.02.001
Turkish journal of trauma & emergency surgery The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis Pubmed: 31475329
CELL TRANSPLANTATION Predictive Value of Degranulating Factors of Neutrophils in Massive Cerebral Infarction 33787356
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPA141Ra01 Recombinant Plasminogen Activator, Urokinase Receptor (uPAR) Positive Control; Immunogen; SDS-PAGE; WB.
APA141Ra01 Active Plasminogen Activator, Urokinase Receptor (uPAR) Cell culture; Activity Assays.
PAA141Ra01 Polyclonal Antibody to Plasminogen Activator, Urokinase Receptor (uPAR) WB; IHC; ICC; IP.
LAA141Ra71 Biotin-Linked Polyclonal Antibody to Plasminogen Activator, Urokinase Receptor (uPAR) WB; IHC; ICC.
MAA141Ra21 Monoclonal Antibody to Plasminogen Activator, Urokinase Receptor (uPAR) WB; IHC; ICC; IP.
MAA141Ra22 Monoclonal Antibody to Plasminogen Activator, Urokinase Receptor (uPAR) WB; IHC; ICC; IP.
SEA141Ra ELISA Kit for Plasminogen Activator, Urokinase Receptor (uPAR) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA141Ra Multiplex Assay Kit for Plasminogen Activator, Urokinase Receptor (uPAR) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.